Ong WL, Romero T, Roy S, Nikitas J, Joseph D, Zapatero A, Malone S, Morgan SC, Steinberg ML, Valle LF, Zaorsky NG, Ma TM, Rettig MB, Nickols N, Jiang T, Reiter RE, Eleswarapu SV, Maldonado X, Sun Y, Nguyen PL, Millar JL, Martin JE, Spratt DE, Kishan AU, on behalf of the Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium Investigators. Testosterone Recovery following ANdrogen Suppression and PrOstate RadioTherapy (TRANSPORT) – A Pooled Analysis of Five Randomized Trials from the Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium. European Urology 2025; 87: 49-57. https://doi.org/10.1016/j.eururo.2024.09.009

Roy S, Fervaha G, Sun Y, Spratt DE, Loblaw A, Kishan AU, Malone S, Saad F, Wallis CJD, Morgan SC. Prostate radiotherapy in low-volume metastatic hormone-sensitive prostate cancer: A network meta-analysis. European Urology 2024; 86: 10-17. https://doi.org/10.1016/j.eururo.2024.03.018

Roy S, Saad F, Wallis CJD, Sun Y, Spratt DE, Akilla R, Kishan AU, Malone S, Morgan SC. Effect of concomitant medications on treatment response and survival in de novo metastatic prostate cancer: Secondary analysis of the LATITUDE study. European Journal of Cancer 2024; 199: 113348. https://doi.org/10.1016/j.ejca.2023.113348

Siva S, Correa R, Ali M, Muacevic A, Ponsky L, Ellis RJ, Lo S, Honishi, Swaminath A, Mclaughlin M, Morgan SC, Cury F, Amahadevan BT, Kaplan I, Chu W, Hannan R, Staehler M, Warner A, Louie A. Five-year outcomes after stereotactic ablative body radiotherapy (SABR) for primary renal cell carcinoma: An individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney). Lancet Oncology 2022; 23(12): 1508-1516. https://doi.org/10.1016/S1470-2045(22)00656-8

Roy S, Sayyid R, Saad F, Sun Y, Lajkosz K, Ong M, Klaassen Z, Malone S, Spratt DE, Wallis CJD, Morgan SC. Addition of docetaxel to androgen receptor axis-targeted therapy and androgen deprivation therapy in metastatic hormone-sensitive prostate cancer: A network meta-analysis. European Urology Oncology 2022; 5(5): 494-502. https://doi.org/10.1016/j.euo.2022.06.003

Morgan SC, Holmes OE, Craig J, Grimes S, Malone S, Long-term outcomes of prostate radiotherapy for newly-diagnosed metastatic prostate cancer. Prostate Cancer and Prostatic Diseases 2021. https://doi.org/10.1038/s41391-021-00339-y

Virgo KS, Rumble RB, de Wit R, Mendelson DS. Smith TJ, Taplin M, Wade JL, Bennett CL, Scher HI, Nguyen PL, Gleave M, Morgan SC, Loblaw DA, Sachdev S, Graham DL, Vapiwala N, Sion AM, Simons VH, Talcott J. Initial management of noncastrate advanced, recurrent or metastatic prostate cancer: ASCO guideline update. Journal of Clinical Oncology 2021. https://doi.org/10.1200/JCO.20.03256

Spratt DE, Malone S, Roy S, Grimes S, Eapen L, Morgan SC, Malone J, Craig J, Dess RT, Jackson W, Kishan AU, Mehra R, Kaffenberger S, Morgan T, Reichert Z, Alumkal J, Michalski JM, Lee WR, Pisansky TM, Feng FY, Shipley WU, Sandler HM, Schipper MJ, Roach M, Sun Y, Lawton CA. Prostate radiotherapy with adjuvant androgen deprivation therapy (ADT) improves metastasis-free survival compared to neoadjuvant ADT: An individual patient meta-analysis. Journal of Clinical Oncology 2021; 39(2): 136-144. https://doi.org/10.1200/JCO.20.02438

Malone S, Roy S, Eapen L, E C, MacRae R, Perry G, Bowen J, Samant R, Morgan SC, Craig J, Malone K, Grimes S. Sequencing of androgen deprivation therapy with external beam radiotherapy in localized prostate cancer: A phase III randomized controlled trial. Journal of Clinical Oncology 2020; 38(6): 593-601. https://doi.org/10.1200/JCO.19.01904

Roy S, Morgan SC. Who dies from prostate cancer? An analysis of the Surveillance, Epidemiology and End Results database. Clinical Oncology 2019; 31(9): 630-636. https://doi.org/10.1016/j.clon.2019.04.012

Morgan SC, Hoffman K, Loblaw DA, Buyyounouski M, Patton C, Barocas D, Bentzen S, Chang M, Efstathiou J, Greany P, Halvorsen P, Koontz B, Lawton C, Leyrer CM, Lin D, Ray M, and Sandler H. Hypofractionated radiation therapy for localized prostate cancer: An ASTRO, ASCO, and AUA evidence-based guideline. Journal of Clinical Oncology 2018;36:3411-3430. https://doi.org/10.1200/JCO.18.01097

Chen R, Rumble RB, Loblaw DA, Finelli A, Ehdaie B, Cooperberg M, Morgan SC, Tyldesley S, Haluschak JJ, Tan W, Justman S, Jain S. Active Surveillance for the management of localized prostate cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology clinical practice guideline endorsement. Journal of Clinical Oncology 2016;34(18):2182-2190. https://doi.org/10.1200/JCO.2015.65.7759

Morgan SC, Parker CC. Local treatment of metastatic cancer—killing the seed or disturbing the soil? Nature Reviews Clinical Oncology 2011;8(8):504-506.

Morgan SC, Waldron TS, Eapen L, Mayhew LA, Winquist E, Lukka H, and Members of the Cancer Care Ontario Genitourinary Cancer Disease Site Group.  Adjuvant radiotherapy following radical prostatectomy for pathologic T3 or margin-positive prostate cancer: a systematic review and meta-analysis.  Radiotherapy and Oncology 2008;88(1):1-9.    

For more publications use this PubMed ID link.